The malignant lymphomas are a heterogeneous group of blood cancers that have distinctive biologic features and overlapping clinical presentations. All are associated with important risks of morbidity and mortality, and yet all also have well-developed treatment pathways that offer therapeutic benefit, including curative potentials. Systemic therapies, including immunotherapies, together with the judicious use of radiotherapy are the mainstays of treatment. For some groups, autologous hematopoietic cell transplant (HCT) offers curative or highly valuable palliative potential when there is progressive lymphoma after initial therapy.1 Allogeneic HCT may offer curative potential for patients who have progressive lymphoma after receiving these treatments.2 The primary mechanism of action leading to benefit from allogeneic HCT is through immunologic pathways associated with graft-vs-lymphoma effects.3
Berg T, Mian HS, Meyer RM. Registry Data and Conditioning Therapy for Allogeneic Hematopoietic Cell Transplant and Lymphoma. JAMA Oncol. 2020;6(7):989–991. doi:10.1001/jamaoncol.2020.1303
Artificial Intelligence Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.